Abstract
Dronedarone is currently used for the treatment of paroxysmal and persistent atrial fibrillation (AF). Pharmacological inhibition of cardiac two-pore-domain potassium (K2P) channels results in action potential prolongation and has recently been proposed as novel antiarrhythmic strategy. We hypothesized that blockade of human K2P channels contributes to the electrophysiological efficacy of dronedarone in AF. Two-electrode voltage clamp and whole-cell patch clamp electrophysiology was used to record K2P currents from Xenopus oocytes and Chinese hamster ovary cells. All functional human K2P channels were screened for dronedarone sensitivity, revealing significant and concentration-dependent inhibition of cardiac K2P2.1 (TREK1; IC50 = 26.7 μM) and K2P3.1 channels (TASK1; IC50 = 18.7 μM) with maximum current reduction of 60.3 and 65.5 % in oocytes. IC50 values obtained from mammalian cells yielded 6.1 μM (K2P2.1) and 5.2 μM (K2P3.1). The molecular mechanism of action was studied in detail. Dronedarone block affected open and closed channels. K2P3.1 currents were reduced in frequency-dependent fashion in contrast to K2P2.1. Mutagenesis studies revealed that amino acid residues implicated in K2P3.1 drug interactions were not required for dronedarone blockade. The class III antiarrhythmic drug dronedarone targets multiple human cardiac two-pore-domain potassium channels, including atrial-selective K2P3.1 currents. K2P current inhibition by dronedarone represents a previously unrecognized mechanism of action that extends the multichannel blocking profile of the drug.
Similar content being viewed by others
References
Aimond F, Beck L, Gautier P, Chérif OK, Davy JM, Lorente P, Nisato D, Vassort G (2000) Cellular and in vivo electrophysiological effects of dronedarone in normal and postmyocardial infarcted rats. J Pharmacol Exp Ther 292:415–424
Altomare C, Barbuti A, Viscomi C, Baruscotti M, DiFrancesco D (2000) Effects of dronedarone on acetylcholine-activated current in rabbit SAN cells. Br J Pharmacol 130:1315–1320
Bayliss DA, Sirois JE, Talley EM (2003) The TASK family: two-pore domain background K+ channels. Mol Interv 4:205–219
Bockenhauer D, Zilberberg N, Goldstein SA (2001) KCNK2: reversible conversion of a hippocampal potassium leak into a voltage-dependent channel. Nat Neurosci 4:486–491
Bogdan R, Goegelein H, Ruetten H (2011) Effect of dronedarone on Na+, Ca2+ and HCN channels. Naunyn Schmiedeberg's Arch Pharmacol 383:347–356
Brohawn SG, del Mármol J, MacKinnon R (2012) Crystal structure of the human K2P TRAAK, a lipid- and mechano-sensitive K + ion channel. Science 335:436–441
Connolly SJ, Camm AJ, Halperin JL, Joyner C, Alings M, Amerena J, Atar D, Avezum Á, Blomström P, Borggrefe M, Budaj A, Chen SA, Ching CK, Commerford P, Dans A, Davy JM, Delacrétaz E, Di Pasquale G, Diaz R, Dorian P, Flaker G, Golitsyn S, Gonzalez-Hermosillo A, Granger CB, Heidbüchel H, Kautzner J, Kim JS, Lanas F, Lewis BS, Merino JL, Morillo C, Murin J, Narasimhan C, Paolasso E, Parkhomenko A, Peters NS, Sim KH, Stiles MK, Tanomsup S, Toivonen L, Tomcsányi J, Torp-Pedersen C, Tse HF, Vardas P, Vinereanu D, Xavier D, Zhu J, Zhu JR, Baret-Cormel L, Weinling E, Staiger C, Yusuf S, Chrolavicius S, Afzal R, Hohnloser SH, Investigators PALLAS (2011) Dronedarone in high-risk permanent atrial fibrillation. N Engl J Med 365:2268–2276
Decher N, Maier M, Dittrich W, Gassenhuber J, Brüggemann A, Busch AE, Steinmeyer K (2001) Characterization of TASK-4, a novel member of the pH-sensitive, two-pore domain potassium channel family. FEBS Lett 492:84–89
Decher N, Wemhöner K, Rinné S, Netter MF, Zuzarte M, Aller MI, Kaufmann SG, Li XT, Meuth SG, Daut J, Sachse FB, Maier SK (2011) Knock-out of the potassium channel TASK-1 leads to a prolonged QT interval and a disturbed QRS complex. Cell Physiol Biochem 28:77–86
Dobrev D, Nattel S (2010) New antiarrhythmic drugs for treatment of atrial fibrillation. Lancet 375:1212–1223
Donner BC, Schullenberg M, Geduldig N, Hüning A, Mersmann J, Zacharowski K, Kovacevic A, Decking U, Aller MI, Schmidt KG (2011) Functional role of TASK-1 in the heart: studies in TASK-1 deficient mice show prolonged cardiac repolarization and reduced heart variability. Basic Res Cardiol 106:75–87
Dorian P (2010) Clinical pharmacology of dronedarone: implications for the therapy of atrial fibrillation. J Cardiovasc Pharmacol Ther 15:15S–18S
Ehrlich JR, Biliczki P, Hohnloser SH, Nattel S (2008) Atrial-selective approaches for the treatment of atrial fibrillation. J Am Coll Cardiol 51:787–792
Ehrlich JR, Nattel S (2009) Novel approaches for pharmacological management of atrial fibrillation. Drugs 69:757–774
Ellinghaus P, Scheubel RJ, Dobrev D, Ravens U, Holtz J, Huetter J, Nielsch U, Morawietz H (2005) Comparing the global mRNA expression profile of human atrial and ventricular myocardium with high-density oligonucleotide arrays. J Thorac Cardiovasc Surg 129:1383–1390
Feliciangeli S, Bendahhou S, Sandoz G, Gounon P, Reichold M, Warth R, Lazdunski M, Barhanin J, Lesage F (2007) Does sumoylation control K2P1/TWIK1 background K+ channels? Cell 130:563–569
Gautier P, Guillemare E, Marion A, Bertrand JP, Tourneur Y, Nisato D (2003) Electrophysiologic characterization of dronedarone in guinea pig ventricular cells. J Cardiovasc Pharmacol 41:191–202
Gierten J, Ficker E, Bloehs R, Schlömer K, Kathöfer S, Scholz E, Zitron E, Kiesecker C, Bauer A, Becker R, Katus HA, Karle CA, Thomas D (2008) Regulation of two-pore-domain (K2P) potassium leak channels by the tyrosine kinase inhibitor genistein. Br J Pharmacol 154:1680–1690
Gierten J, Ficker E, Bloehs R, Schweizer PA, Zitron E, Scholz E, Karle C, Katus HA, Thomas D (2010) The human cardiac K2P3.1 (TASK-1) potassium leak channel is a molecular target for the class III antiarrhythmic drug amiodarone. Naunyn Schmiedeberg's Arch Pharmacol 381:261–270
Gierten J, Hassel D, Schweizer PA, Becker R, Katus HA, Thomas D (2012) Identification and functional characterization of zebrafish K2P10.1 (TREK2) two-pore-domain K+ channels. Biochim Biophys Acta 1818:33–41
Goonetilleke L, Quayle J (2012) TREK-1 K+ channels in the cardiovascular system: their significance and potential as a therapeutic target. Cardiovasc Ther 30:e23–e29
Guillemare E, Marion A, Nisato D, Gautier P (2000) Inhibitory effects of dronedarone on muscarinic K + current in guinea pig atrial cells. J Cardiovasc Pharmacol 36:802–805
Gurney A, Manoury B (2009) Two-pore potassium channels in the cardiovascular system. Eur Biophys J 38:305–318
Hohnloser SH, Crijns HJ, van Eickels M, Gaudin C, Page RL, Torp-Pedersen C, Connolly SJ, Investigators ATHENA (2009) Effect of dronedarone on cardiovascular events in atrial fibrillation. N Engl J Med 360:668–678
Iwasaki YK, Nishida K, Kato T, Nattel S (2011) Atrial fibrillation pathophysiology: implications for management. Circulation 124:2264–2274
Kathofer S, Thomas D, Karle CA (2005) The novel antiarrhythmic drug dronedarone: comparison with amiodarone. Cardiovasc Drug Rev 23:217–230
Lalevée N, Nargeot J, Barrére-Lemaire S, Gautier P, Richard S (2003) Effects of amiodarone and dronedarone on voltage-dependent sodium current in human cardiomyocytes. J Cardiovasc Electrophysiol 14:885–890
Lalevée N, Monier B, Sénatore S, Perrin L, Sémériva M (2006) Control of cardiac rhythm by ORK1, a Drosophila two-pore domain potassium channel. Curr Biol 16:1502–1508
Limberg SH, Netter MF, Rolfes C, Rinné S, Schlichthörl G, Zuzarte M, Vassiliou T, Moosdorf R, Wulf H, Daut J, Sachse FB, Decher N (2011) TASK-1 channels may modulate action potential duration of human atrial cardiomyocytes. Cell Physiol Biochem 28:613–624
Liu W, Saint DA (2004) Heterogeneous expression of tandem-pore K+ channel genes in adult and embryonic rat heart quantified by real-time polymerase chain reaction. Clin Exp Pharmacol Physiol 31:174–178
Lopes CM, Gallagher PG, Buck ME, Butler MH, Goldstein SA (2000) Proton block and voltage gating are potassium-dependent in the cardiac leak channel Kcnk3. J Biol Chem 275:16969–16978
Marban E (2002) Cardiac channelopathies. Nature 415:213–218
Milac AL, Anishkin A, Fatakia SN, Chow CC, Sukharev S, Guy HR (2011) Structural models of TREK channels and their gating mechanism. Channels (Austin) 5:23–33
Miller AN, Long SB (2012) Crystal structure of the human two-pore domain potassium channel K2P1. Science 335:432–436
Obers S, Staudacher I, Ficker E, Dennis A, Koschny R, Erdal H, Bloehs R, Kisselbach J, Karle CA, Schweizer PA, Katus HA, Thomas D (2010) Multiple mechanisms of hERG liability: K+ current inhibition, disruption of protein trafficking, and apoptosis induced by amoxapine. Naunyn Schmiedeberg's Arch Pharmacol 381:385–400
Patel A, Honore E (2001) Properties and regulation of mammalian 2P domain K+ channels. Trends Neurosci 24:339–346
Putzke C, Wemhöner K, Sachse FB, Rinné S, Schlichthörl G, Li XT, Jaé L, Eckhardt I, Wischmeyer E, Wulf H, Preisig-Müller R, Daut J, Decher N (2007) The acid-sensitive potassium channel TASK-1 in rat cardiac muscle. Cardiovasc Res 75:59–68
Rahm AK, Gierten J, Kisselbach J, Staudacher I, Staudacher K, Schweizer PA, Becker R, Katus HA, Thomas D (2012) Protein kinase C-dependent activation of human K2P18.1 K+ channels. Br J Pharmacol 166:764–773
Rajan S, Plant LD, Rabin ML, Butler MH, Goldstein SA (2005) Sumoylation silences the plasma membrane leak K+ channel K2P1. Cell 121:37–47
Ravens U (2010) Novel pharmacological approaches for antiarrhythmic therapy. Naunyn Schmiedeberg's Arch Pharmacol 381:187–193
Ridley JM, Milnes JT, Witchel HJ, Hancox JC (2004) High affinity HERG K(+) channel blockade by the antiarrhythmic agent dronedarone: resistance to mutations of the S6 residues Y652 and F656. Biochem Biophys Res Commun 325:883–891
Schweizer PA, Becker R, Katus HA, Thomas D (2011) Dronedarone: current evidence for its safety and efficacy in the management of atrial fibrillation. Drug Des Devel Ther 5:27–39
Seyler C, Duthil-Straub E, Zitron E, Gierten J, Scholz EP, Fink RH, Karle CA, Becker R, Katus HA, Thomas D (2012) TASK1 (K2P3.1) K+ current inhibition by endothelin-1 is mediated by Rho kinase-dependent channel phosphorylation. Br J Pharmacol 165:1467–1475
Staudacher K, Baldea I, Kisselbach J, Staudacher I, Rahm AK, Schweizer PA, Becker R, Katus HA, Thomas D (2011a) Alternative splicing determines mRNA translation initiation and function of human K2P10.1 K+ channels. J Physiol 589:3709–3720
Staudacher K, Staudacher I, Ficker E, Seyler C, Gierten J, Kisselbach J, Rahm AK, Trappe K, Schweizer PA, Becker R, Katus HA, Thomas D (2011b) Carvedilol targets human K2P3.1 (TASK1) K+ leak channels. Br J Pharmacol 163:1099–1110
Staudacher I, Wang L, Wan X, Obers S, Wenzel W, Tristram F, Koschny R, Staudacher K, Kisselbach J, Koelsch P, Schweizer PA, Katus HA, Ficker E, Thomas D (2011c) hERG K+ channel-associated cardiac effects of the antidepressant drug desipramine. Naunyn Schmiedeberg's Arch Pharmacol 383:119–139
Streit AK, Netter MF, Kempf F, Walecki M, Rinné S, Bollepalli MK, Preisig-Müller R, Renigunta V, Daut J, Baukrowitz T, Sansom MS, Stansfeld PJ, Decher N (2011) A specific two-pore domain potassium channel blocker defines the structure of the TASK-1 open pore. J Biol Chem 286:13977–13984
Thomas D, Goldstein SAN (2009) Two-P-domain (K2P) potassium channels: leak conductance regulators of excitability. In: Squire LR (ed) Encyclopedia of neuroscience. Academic Press, Oxford, pp 1207–1220
Thomas D, Kathofer S, Zhang W, Wu K, Wimmer AB, Zitron E, Kreye VA, Katus HA, Schoels W, Karle CA, Kiehn J (2003) Acute effects of dronedarone on both components of the cardiac delayed rectifier K+ current, HERG and KvLQT1/minK potassium channels. Br J Pharmacol 140:996–1002
Thomas D, Plant LD, Wilkens CM, McCrossan ZA, Goldstein SAN (2008) Alternative translation initiation in rat brain yields K2P2.1 potassium channels permeable to sodium. Neuron 58:859–870
Thomas D, Wendt-Nordahl G, Röckl K, Ficker E, Brown AM, Kiehn J (2001) High-affinity blockade of human ether-a-go-go-related gene human cardiac potassium channels by the novel antiarrhythmic drug BRL-32872. J Pharmacol Exp Ther 297:753–761
Varró A, Takács J, Németh M, Hála O, Virág L, Iost N, Baláti B, Agoston M, Vereckei A, Pastor G, Delbruyère M, Gautier P, Nisato D, Papp JG (2001) Electrophysiological effects of dronedarone (SR 33589), a noniodinated amiodarone derivative in the canine heart: comparison with amiodarone. Br J Pharmacol 133:625–634
Voigt N, Rozmaritsa N, Trausch A, Zimniak T, Christ T, Wettwer E, Matschke K, Dobrev D, Ravens U (2010) Inhibition of IK, ACh current may contribute to clinical efficacy of class I and class III antiarrhythmic drugs in patients with atrial fibrillation. Naunyn Schmiedeberg's Arch Pharmacol 381:251–259
Watanabe Y, Kimura J (2008) Acute inhibitory effect of dronedarone, a noniodinated benzofuran analogue of amiodarone, on Na+/Ca2+ exchange current in guinea pig cardiac ventricular myocytes. Naunyn Schmiedeberg's Arch Pharmacol 377:371–376
Xian Tao L, Dyachenko V, Zuzarte M, Putzke C, Preisig-Müller R, Isenberg G, Daut J (2006) The stretch-activated potassium channel TREK-1 in rat cardiac ventricular muscle. Cardiovasc Res 69:86–97
Zhang YH, Colenso CK, Sessions RB, Dempsey CE, Hancox JC (2011) The hERG K(+) channel S4 domain L532P mutation: characterization at 37 °C. Biochim Biophys Acta 1808:2477–2487
Acknowledgments
We thank Jennifer Gütermann, Christine Jekel, and Bianca Menrath for excellent technical assistance and Stefan Kallenberger for critical comments and helpful discussions. This work was supported by grants from the German Heart Foundation/German Foundation of Heart Research (Kaltenbach Scholarship to F.W. and project F/06/10 to D.T.) and from the Max Planck Society (TANDEM project to P.A.S.).
Conflict of interest
D.T. serves on advisory boards for and received financial support for lectures from Sanofi Aventis. The remaining authors report no potential conflicts of interest.
Author information
Authors and Affiliations
Corresponding author
Additional information
C. Schmidt and F. Wiedmann contributed equally to this work.
Rights and permissions
About this article
Cite this article
Schmidt, C., Wiedmann, F., Schweizer, P.A. et al. Novel electrophysiological properties of dronedarone: inhibition of human cardiac two-pore-domain potassium (K2P) channels. Naunyn-Schmiedeberg's Arch Pharmacol 385, 1003–1016 (2012). https://doi.org/10.1007/s00210-012-0780-9
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00210-012-0780-9